The offering is dilutive for a micro-cap biotech with a $12M market cap, signaling near-term cash needs. Monitor for the closing on August 31, 2026, and any subsequent updates on cash runway or clinical trial progress for GLIX1 or motixafortide. The warrant amendment reduces some overhang but does not change the bearish read on the primary offering.
Price Chart
Executive Summary
BioLineRx announced a $3.75M registered direct offering and concurrent private placement, selling 1,348,921 ADSs at $2.78/ADS and issuing warrants for up to 2,023,382 additional ADSs at the same price. The offering, expected to close August 31, 2026, is dilutive for a company with a $12M market cap and represents a near-term cash need, though the proceeds are earmarked for R&D and working capital. The concurrent warrant amendment for an existing investor reduces dilution overhang slightly but does not offset the immediate dilution from the new shares.
Key Financial Metrics
Key Facts
- Gross proceeds of $3.75M from the offering
- 1,348,921 ADSs sold at $2.78 per ADS in registered direct offering
- Warrants to purchase up to 2,023,382 additional ADSs at $2.78 per ADS, expiring in 5 years
- Warrant amendment reduces exercise price of 277,273 existing ADS warrants to $2.78 and extends expiration to August 31, 2031
- Offering expected to close on or about August 31, 2026
- Proceeds to be used for R&D and working capital
Financial Impact
Gross proceeds of $3.75M from the offering; dilution from 1,348,921 new ADSs plus potential additional dilution from warrants for up to 2,023,382 ADSs
Risk Factors
- Dilution from new ADSs and potential exercise of warrants
- Limited cash runway for a clinical-stage company with no near-term revenue from GLIX1
- Execution risk in R&D and working capital deployment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302862746 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 6-K | $2.04 | awaiting T+20 | — | $2.01 (−1.47%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.01 (+13.36%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.01 (−17.28%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.01 (−21.77%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.01 (−33.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers